Understanding multimorbidity to improve prevention
A collaborative research project between IDIBELL-ICO, Jordi Gol IDIAP and IGTP identifies the main diseases that contribute to it
Understanding multimorbidity to improve prevention Read More »
2018
Looking for a fast, effective treatment for autoimmune rheumatic diseases
Autoimmune rheumatic diseases like rheumatoid arthritis, lupus and scleroderma are debilitating and occasionally life-threatening. An EU and industry-funded project aims to improve treatment by getting the right therapies to the right patients, fast.
Looking for a fast, effective treatment for autoimmune rheumatic diseases Read More »
Open Access Week at IDIBELL
The theme for the 2018 International Open Access Week, to be held October 22-28, will be “designing equitable foundations for open knowledge.” This year’s theme reflects a scholarly system in transition. While governments, funders, universities, publishers, and scholars are increasingly adopting open policies and practices, how these are actually implemented is still in flux.
Open Access Week at IDIBELL Read More »
IDIBELL’s health innovation model visits Barcelona and Japan
IDIBELL takes part in the HEALTHIO and BioJapan trade fairs
IDIBELL’s health innovation model visits Barcelona and Japan Read More »
IDIBELL and ICO turn pink for Breast Cancer World Day
Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) will join the pink movement associated with the celebration of Breast Cancer World Day. Thus, the facade of the Duran i Reynals Hospital (Granvia de l’Hospitalet 199-203) will turn pink, the night of Friday, October 19th, World Day Against Breast Cancer, to remember the importance of early
IDIBELL and ICO turn pink for Breast Cancer World Day Read More »
New scientific-technical equipment for IDIBELL
The Spanish ministry of science, innovation and universities has awarded IDIBELL a grant (EQC2018-005246-P) worth approximately 93000€ to purchase a Seahorse 96, a high-throughput equipment for cellular metabolism and mitochondrial function analysis. This grant belongs to the 2018 call for the acquisition of scientific-technical equipment within the National R&D&I Plan 2017-2020.
New scientific-technical equipment for IDIBELL Read More »
New therapeutic strategies for breast cancer
The risk of developing breast cancer is largely determined by the ability of the cells to repair damage to their DNA and, at the same time, by the regulation of the “stem cells” that may eventually become tumors. However, it is unknown how these two fundamental processes co-regulate. In a recent study, IDIBELL –
New therapeutic strategies for breast cancer Read More »
Statement on Dr Manel Esteller leaving IDIBELL
The Bellvitge Biomedical Research Institute (IDIBELL) states that Dr Manel Esteller, ICREA researcher, professor at the University of Barcelona, and until now, coordinator of the Epigenetics and Cancer Biology Program (PEBC) at IDIBELL, has been appointed director of the Josep Carreras Leukaemia Research Institute, a position that implies the termination of his employment relationship with
Statement on Dr Manel Esteller leaving IDIBELL Read More »
400,000 dollars to fight prostate cancer
Dr. Álvaro Aytés (IDIBELL – ICO / ProCure) project receives an Idea Development Award from the American Department of Defense (DoD) within its Prostate Cancer Research Program.
400,000 dollars to fight prostate cancer Read More »
Bioinformatics deciphers the metabolic characteristics of 25 types of cancer
Thanks to a bioinformatics analysis of 9,428 tumor samples, vulnerabilities potentially leading to new, more precise treatments are also identified
Bioinformatics deciphers the metabolic characteristics of 25 types of cancer Read More »